De-Risked NDA Resubmission and TDAPA Tailwinds Support Buy Rating on Unicycive and OLC Commercial Upside
I'm PortAI, I can summarize articles.
Analyst Jason McCarthy from Maxim Group has maintained a Buy rating on Unicycive Therapeutics with a price target of $30.00. He believes the resubmission of the NDA for oxylanthanum carbonate (OLC) is de-risked due to previous FDA issues being resolved. McCarthy highlights the company's strong balance sheet and the strategic timing of the TDAPA reimbursement window, which could enhance OLC's market uptake. He cites additional Phase 2 data supporting OLC's advantages in treatment compliance, reinforcing his positive outlook on Unicycive's shares.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments